P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

• Nicholas Short,
• Walid Macaron,
• Courtney Dinardo,
• Naval Daver,
• Musa Yilmaz,
• Gautam Borthakur,
• Guillermo Montalban-Bravo,
• Guillermo Garcia-Manero,
• Ghayas Issa,
• Koji Sasaki,
• Jan Burger,
• Abhishek Maiti,
• Yesid Alvarado,
• Jennifer Thankachan,
• Regina Abramova,
• Lewis Nasr,
• Cedric Nasnas,
• Marianne Zoghbi,
• Tapan Kadia,
• Marina Konopleva,
• Hagop Kantarjian,
• Farhad Ravandi

Affiliations

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Walid Macaron

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Courtney Dinardo

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Naval Daver

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Musa Yilmaz

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Gautam Borthakur

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Guillermo Montalban-Bravo

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Guillermo Garcia-Manero

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Ghayas Issa

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Koji Sasaki

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Jan Burger

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Abhishek Maiti

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Yesid Alvarado

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Jennifer Thankachan

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Regina Abramova

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Lewis Nasr

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Cedric Nasnas

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Marianne Zoghbi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Tapan Kadia

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Marina Konopleva

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States